BioSpace News Archive

Seelos Therapeutics, Inc. today announced the placement of a $22.0 million senior secured convertible note (the “Note”) and shares of Seelos common stock (the “Closing Shares”) to Lind Global Asset Management V, LLC, managed by The Lind Partners, a New York institutional fund manager and an existing investor in Seelos.

PharmaTher Holdings Ltd. is pleased to announce that it has applied with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for ketamine to treat Status Epilepticus (“SE”), a rare neurological disorder requiring emergency treatment for a seizure.

Vaccine demonstrates protection against COVID-19 related hospitalization and death, and across different variants.

Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (FSE: 3XI), a leading biotech company in fast-acting psychedelics is pleased to announce the successful design of an oromucosal solid pharmaceutical form obtained by 3D printing using selective laser sintering.

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Bob Smith, Vice President, Pfizer Rare Disease, at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 5:10 p.m. Eastern Standard Time.

The Innovative Hot & Cold Contrast Therapy Device for Relief of Chronic Pain.

Brand Institute is proud to announce its successful partnership with Takeda Pharmaceuticals Company Limited in naming the first treatment approved by the US Food & Drug Administration (FDA) for adults and pediatric patients with post-transplant cytomegalovirus (CMV) infection that does not respond to available antiviral treatment for CMV.

Variant, a company dedicated to developing innovative treatments for inherited eye orphan diseases, announces the decision of the European Commission to grant Orphan Drug Designation (ODD) for VAR002 for the treatment of Leber congenital amaurosis (LCA) and Cone-rod dystrophy (CORD).

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), reports that the Annual General Meeting (AGM) of Shareholders of the Company will be held on December 27, 2021 in Tel Aviv, Israel.

Amgen (NASDAQ:AMGN) will present at the 2021 Evercore ISI Healthcare Conference at 5:10 p.m. ET on Tuesday, Nov. 30, 2021. Rob Lenz, M.D., Ph.D., senior vice president of Global Development at Amgen will present at the conference.